All Stories

  1. Is it time to re-think the use of etravirine in patients with available genotypic resistance test?

    Article • Infectious Diseases, April 2019, Taylor & Francis

    Dr Antonio Di Biagio

  2. Ibalizumab and Fostemsavir in the Management of Heavily Pre-Treated HIV-infected Patients

    Article • Recent Patents on Anti-Infective Drug Discovery, January 2019, Bentham Science Publishers

    Dr Antonio Di Biagio

  3. Bedaquiline: A New Hope for Shorter and Better Anti-Tuberculosis Regimens

    Article • Recent Patents on Anti-Infective Drug Discovery, October 2018, Bentham Science Publishers

    Dr Antonio Di Biagio

  4. HCV elimination plan leads to significant benefits in managing liver-related diseases and hospital interventions: a regional simulation

    Article • Expert Review of Pharmacoeconomics & Outcomes Research, October 2018, Taylor & Francis

    Dr Giovanni Cenderello, Dr Antonio Di Biagio

  5. First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison

    Article • HIV Medicine, May 2018, Wiley

    Dr Antonio Di Biagio

  6. Durability, safety, and efficacy of rilpivirine in clinical practice: results from the SCOLTA Project

    Article • Infection and Drug Resistance, April 2018, Dove Medical Press

    Dr Antonio Di Biagio, Bonfanti Paolo, Giustino Parruti

  7. Use of quantitative ultrasound as bone mineral density evaluation in an Italian female population living with HIV: A real-life experience

    Article • Journal of Women & Aging, January 2018, Taylor & Francis

    Dr Antonio Di Biagio

  8. Cost per care of the first year of direct antiviral agents in the Liguria Region: a multicenter analysis

    Article • ClinicoEconomics and Outcomes Research, May 2017, Dove Medical Press

    Dr Giovanni Cenderello, Dr Antonio Di Biagio

  9. Potential role of raltegravir-based therapy to induce rapid viral decay in highly viraemic HIV-infected neonates

    Article • Journal of Chemotherapy, July 2016, Maney Publishing

    Dr Antonio Di Biagio

  10. Budget impact analysis of sofosbuvir-based regimens for the treatment of HIV/HCV-coinfected patients in northern Italy: a multicenter regional simulation

    Article • ClinicoEconomics and Outcomes Research, December 2015, Dove Medical Press

    Dr Giovanni Cenderello, Dr Antonio Di Biagio, Mauro Giacomini

  11. Efficacy, safety, and patient acceptability of elvitegravir/cobicistat/emtricitabine/tenofovir in the treatment of HIV/AIDS

    Article • Patient Preference and Adherence, August 2015, Dove Medical Press

    Dr Antonio Di Biagio

  12. Behind the screens: Clinical decision support methodologies – A review

    Article • Health Policy and Technology, March 2015, Elsevier

    Dr Antonio Di Biagio

  13. Efficacy and Safety of Darunavir/Ritonavir Plus Etravirine Dual Regimen in Antiretroviral Therapy–Experienced Patients: A Multicenter Clinical Experience

    Article • HIV Clinical Trials, August 2014, Taylor & Francis

    Dr Antonio Di Biagio

  14. Liver Enzyme Elevation During Darunavir-Based Antiretroviral Treatment in HIV-1–Infected Patients With or Without Hepatitis C Coinfection: Data from the ICONA Foundation Cohort

    Article • HIV Clinical Trials, August 2014, Taylor & Francis

    Dr Antonio Di Biagio

  15. The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy

    Article • Journal of Medical Virology, July 2014, Wiley

    Dr Antonio Di Biagio

  16. Innate immunity cell activation in virologically suppressed HIV-infected maraviroc-treated patients

    Article • AIDS, April 2014, Wolters Kluwer Health

    Dr Antonio Di Biagio

  17. Decreasing cardiovascular risk in HIV infection between 2005 and 2011

    Article • AIDS, February 2014, Wolters Kluwer Health

    Dr Antonio Di Biagio

  18. Genotypic Determination of HIV Tropism in a Cohort of Patients Perinatally Infected With HIV-1 and Exposed to Antiretroviral Therapy

    Article • HIV Clinical Trials, February 2014, Taylor & Francis

    Dr Antonio Di Biagio

  19. Four years data of raltegravir-based salvage therapy in HIV-1-infected, treatment-experienced patients: the SALIR-E Study

    Article • International Journal of Antimicrobial Agents, February 2014, Elsevier

    Dr Antonio Di Biagio

  20. Maraviroc as Intensification Strategy in HIV-1 Positive Patients with Deficient Immunological Response: an Italian Randomized Clinical Trial

    Article • PLoS ONE, November 2013, PLOS

    Dr Antonio Di Biagio

  21. Pharmacokinetics of Lopinavir Determined with an ELISA Test in Youths with Perinatally Acquired HIV

    Article • The Indian Journal of Pediatrics, September 2013, Springer Science + Business Media

    Dr Antonio Di Biagio

  22. The Ligurian Human Immunodeficiency Virus Clinical Network: A Web Tool to Manage Patients With Human Immunodeficiency Virus in Primary Care and Multicenter Clinical Trials

    Article • Medicine 2 0, August 2013, JMIR Publications Inc.

    Dr Antonio Di Biagio

  23. Use of raltegravir in a late presenter HIV-1 woman in advanced gestational age: case report and literature review

    Article • Journal of Chemotherapy, June 2013, Taylor & Francis

    Dr Antonio Di Biagio

  24. Safety and durability in a cohort of HIV-1 positive patients treated with once and twice daily darunavir-based therapy (SCOLTA Project)

    Article • Biomedicine & Pharmacotherapy, May 2013, Elsevier

    Dr Antonio Di Biagio

  25. Successfully treated HIV-infected patients have differential expression of NK cell receptors (NKp46 and NKp30) according to AIDS status at presentation

    Article • Immunology Letters, April 2013, Elsevier

    Dr Antonio Di Biagio

  26. Raltegravir central nervous system tolerability in clinical practice

    Article • AIDS, November 2012, Wolters Kluwer Health

    Dr Antonio Di Biagio

  27. Case report: Management and HBV sequencing in a patient co‐infected with HBV and HIV failing tenofovir

    Article • Journal of Medical Virology, July 2012, Wiley

    Dr Antonio Di Biagio

  28. 96 Week Follow-Up of HIV-Infected Patients in Rescue with Raltegravir Plus Optimized Backbone Regimens: A Multicentre Italian Experience

    Article • PLoS ONE, July 2012, PLOS

    Dr Antonio Di Biagio

  29. Simplification to monotherapy with lopinavir/ritonavir in adolescents with vertically acquired HIV-1 infection

    Article • Journal of Chemotherapy, February 2012, Taylor & Francis

    Dr Antonio Di Biagio

  30. HIV and Accelerated Atheroprogression: Role of Antiretroviral Therapy

    Article • Current Pharmaceutical Biotechnology, January 2012, Bentham Science Publishers

    Dr Antonio Di Biagio

  31. Effects of hepatitis C virus infection on the pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected patients

    Article • Journal of Infection and Chemotherapy, January 2012, Elsevier

    Dr Antonio Di Biagio, Professor Arianna Loregian

  32. Lamivudine resistance mutations in European patients with hepatitis B and patients co‐infected with HIV and hepatitis B

    Article • Journal of Medical Virology, September 2011, Wiley

    Dr Antonio Di Biagio

  33. Patient-reported outcomes and low-level residual HIV-RNA in adolescents perinatally infected with HIV-1 after switching to one-pill fixed-dose regimen

    Article • AIDS Care, July 2011, Taylor & Francis

    Dr Antonio Di Biagio

  34. Nevirapine-Based Regimens in Routine Clinical Settings: Results from a Large Italian Cohort of HIV-1 Infected Adults

    Article • Current Drug Safety, July 2011, Bentham Science Publishers

    Dr Antonio Di Biagio

  35. A Prognostic Model for Estimating the Time to Virologic Failure in HIV-1 Infected Patients Undergoing a New Combination Antiretroviral Therapy Regimen

    Article • BMC Medical Informatics and Decision Making, June 2011, Springer Science + Business Media

    Dr Antonio Di Biagio

  36. Osteonecrosis in human immunodeficiency virus (HIV)-infected patients: a multicentric case–control study

    Article • Journal of Bone and Mineral Metabolism, January 2011, Springer Science + Business Media

    Dr Antonio Di Biagio

  37. Safety and efficacy of pegylated interferon and ribavirin in adolescents with human immunodeficiency virus and hepatitis C virus acquired perinatally

    Article • Journal of Medical Virology, May 2010, Wiley

    Dr Antonio Di Biagio

  38. Emerging mutations at virological failure of HAART combinations containing tenofovir and lamivudine or emtricitabine

    Article • AIDS, April 2010, Wolters Kluwer Health

    Dr Antonio Di Biagio, annalisa de silvestri

  39. Evaluation of insulin resistance in a cohort of HIV-infected youth

    Article • Current Diabetes Reports, July 2009, Springer Science + Business Media

    Dr Antonio Di Biagio

  40. Clinical course of classic Kaposi's sarcoma in HIV-negative patients treated with the HIV protease inhibitor indinavir

    Article • AIDS, February 2009, Wolters Kluwer Health

    Dr Antonio Di Biagio

  41. Whole body bone scintigraphy in tenofovir-related osteomalacia: a case report

    Article • Journal of Medical Case Reports, January 2009, Springer Science + Business Media

    Dr Antonio Di Biagio

  42. Letter to the Editor: Successful Rescue Therapy with Raltegravir (MK-0518) and Etravirine (TMC125) in an HIV-Infected Patient Failing All Four Classes of Antiretroviral Drugs

    Article • AIDS Patient Care and STDs, May 2008, Mary Ann Liebert Inc

    Dr Antonio Di Biagio

  43. Infectious complications of cancer chemotherapy in HIV patients

    Article • Current Infectious Disease Reports, March 2008, Springer Science + Business Media

    Dr Antonio Di Biagio

  44. Different evidence of key amprenavir resistance mutations on the efficacy of darunavir

    Article • AIDS, January 2008, Wolters Kluwer Health

    Dr Antonio Di Biagio

  45. Effects of the Change From Stavudine to Tenofovir in Human Immunodeficiency Virus-Infected Children Treated With Highly Active Antiretroviral Therapy

    Article • The Pediatric Infectious Disease Journal, January 2008, Wolters Kluwer Health

    Dr Antonio Di Biagio

  46. Effects on growth after switching protease inhibitors to efavirenz in HIV-1-infected children

    Article • International Journal of Antimicrobial Agents, February 2007, Elsevier

    Dr Antonio Di Biagio

  47. Candidainfections in the intensive care unit: epidemiology, risk factors and therapeutic strategies

    Article • Expert Review of Anti-infective Therapy, October 2006, Taylor & Francis

    Dr Antonio Di Biagio

  48. Benign Lymphoepithelial Parotid Lesions in Vertically HIV-Infected Patients

    Article • AIDS Patient Care and STDs, August 2006, Mary Ann Liebert Inc

    Dr Antonio Di Biagio

  49. Clinically Stable Treatment-Experienced Adults Receiving Tenofovir and Didanosine

    Article • HIV Clinical Trials, February 2006, Taylor & Francis

    Dr Antonio Di Biagio

  50. Predictive Factors of Hyperlipidemia in HIV-Infected Subjects Receiving Lopinavir/Ritonavir

    Article • AIDS Research and Human Retroviruses, February 2006, Mary Ann Liebert Inc

    Dr Antonio Di Biagio

  51. Long-term antiretroviral efficacy and safety of lopinavir/ritonavir in HAART-experienced subjects: 4 year follow-up study

    Article • AIDS, November 2005, Wolters Kluwer Health

    Dr Antonio Di Biagio

  52. Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individuals

    Article • International Journal of Antimicrobial Agents, July 2005, Elsevier

    Dr Antonio Di Biagio

  53. Role of linezolid in the treatment of orthopedic infections

    Article • Expert Review of Anti-infective Therapy, June 2005, Taylor & Francis

    Dr Antonio Di Biagio

  54. Consecutive blood lactate assessment in HIV-infected children: correlation with therapy and clinical characteristics

    Article • International Journal of Infectious Diseases, May 2005, Elsevier

    Dr Antonio Di Biagio

  55. Treatment of HIV infection in children

    Article • Reviews in Medical Microbiology, January 2005, Wolters Kluwer Health

    Dr Antonio Di Biagio

  56. Successful treatment of methicillin-resistant Staphylococcus aureus endocarditis with linezolid

    Article • International Journal of Antimicrobial Agents, July 2004, Elsevier

    Dr Antonio Di Biagio

  57. New antibiotics for treatment of serious infections due to antibiotic-resistant Gram-positive cocci

    Article • Reviews in Medical Microbiology, July 2004, Wolters Kluwer Health

    Dr Antonio Di Biagio

  58. Fatal lactic acidosis and mimicking Guillain-Barré syndrome in an adolescent with human immunodeficiency virus infection

    Article • The Pediatric Infectious Disease Journal, July 2003, Wolters Kluwer Health

    Dr Antonio Di Biagio

  59. The effect of formulary restriction in the use of antibiotics in an Italian hospital

    Article • European Journal of Clinical Pharmacology, September 2001, Springer Science + Business Media

    Dr Antonio Di Biagio

  60. Linezolid treatment of prosthetic hip infections due to methicillin-resistant Staphylococcus aureus (MRSA)

    Article • Journal of Orthopaedics and Traumatology, December 2000, Springer Science + Business Media

    Dr Antonio Di Biagio

  61. Use of antibiotics in an Italian children’s hospital, 1993–1995; clinical and economic considerations

    Article • International Journal of Antimicrobial Agents, February 2000, Elsevier

    Dr Antonio Di Biagio

  62. The relationship between ritonavir plasma levels and side-effects: implications for therapeutic drug monitoring

    Article • AIDS, October 1999, Wolters Kluwer Health

    Dr Antonio Di Biagio